Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.

about

Comparison of Somatostatin Receptor 2-Targeting PET Tracers in the Detection of Mouse Atherosclerotic Plaques.NACP 2014 and the Turku PET symposium: The interaction between therapy and imaging

P2860

Q52999991-9B4C483B-C593-42F1-A3BB-BA8E408A0886 Q57621752-9256AC3E-1985-49FC-8D95-9F13CF5078BE

P2860

Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.

Item

http://www.wikidata.org/entity/Q38981899

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Feasibility of experimental BT ...... receptor 2-targeted therapies.

@en

type

Item

label

Feasibility of experimental BT ...... receptor 2-targeted therapies.

@en

prefLabel

Feasibility of experimental BT ...... receptor 2-targeted therapies.

@en

P1476

Feasibility of experimental BT ...... receptor 2-targeted therapies.

@en

P2093

Aida Kiviniemi

http://www.w3.org/2001/XMLSchema#string

Anu Autio

http://www.w3.org/2001/XMLSchema#string

Henri Sipilä

http://www.w3.org/2001/XMLSchema#string

Jere Kurkipuro

http://www.w3.org/2001/XMLSchema#string

Maria Gardberg

http://www.w3.org/2001/XMLSchema#string

Meeri Käkelä

http://www.w3.org/2001/XMLSchema#string

Vanina D Heuser

http://www.w3.org/2001/XMLSchema#string

Xiang-Guo Li

http://www.w3.org/2001/XMLSchema#string

P2860

(68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives.

Local injection of the 90Y-labelled peptidic vector DOTATOC to control gliomas of WHO grades II and III: an extended pilot study.

Resolution, sensitivity and precision with autoradiography and small animal positron emission tomography: implications for functional brain imaging in animal research.

Growing vascular endothelial cells express somatostatin subtype 2 receptors

Sstr2A: a relevant target for the delivery of genes into human glioblastoma cells using fiber-modified adenoviral vectors.

The inhibitory effect of a novel cytotoxic somatostatin analogue AN-162 on experimental glioblastoma.

The somatostatin receptor family.

Somatostatin receptor subtype 2A immunohistochemistry using a new monoclonal antibody selects tumors suitable for in vivo somatostatin receptor targeting.

Response of recurrent high-grade glioma to treatment with (90)Y-DOTATOC.

Translating the concept of peptide labeling with 5-deoxy-5-[18F]fluororibose into preclinical practice: 18F-labeling of Siglec-9 peptide for PET imaging of inflammation.

P304

1125-1134

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/0284186X.2014.925577

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-06-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24957558

http://www.w3.org/2001/XMLSchema#string

Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.

about

P2860

P2860

Feasibility of experimental BT4C glioma models for somatostatin receptor 2-targeted therapies.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698